Why the study?
Doxorubicin use is limited by dose-dependent cardiotoxicity, and the application of acetylation as a therapeutic target remains in its initial stage with further studies required to clarify its complex network.
Design
Review
Authors
Loading...
Acetylation may offer new targets to mitigate DOX cardiotoxicity; leaves open its role beyond ROS and need for clinical validation.
Key points are not available for this paper at this time.
Li et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: